Gall-Stones and Oral Contraceptives

1975 ◽  
Vol 3 (2) ◽  
pp. 59-62 ◽  
Author(s):  
J M T Howat ◽  
C B Jones ◽  
P F Schofield

An investigation into oral contraceptive use in female patients with gallstones has been undertaken. Comparison between a group of 50 young women aged 20-45 years with gall-stones and a group of young women of similar age and parity without gall-stones, shows a significantly higher incidence of contraceptive use in the gall-stone patients (p > 0·001). It is suggested that oral contraceptives may predispose pre-menopausal women to gall-stone formation and this is discussed in relationship to the physical and chemical alterations in biliary secretion produced by hormonal changes.

2010 ◽  
Vol 63 (9-10) ◽  
pp. 657-661 ◽  
Author(s):  
Milena Veljkovic ◽  
Slavimir Veljkovic

Introduction. Oral contraceptives, mainly combined monophasic pills, are widely used by young women who expect their physicians to prescribe them safe drugs which will not harm their health and which will simplify their life. Numerous epidemiologic studies have been performed to determine the relation between oral contraceptive use and the development of neoplasms. Breast cancer. An increased incidence of breast cancer has occurred simultaneously with the growing use of oral contraceptives. The possibility of a link between the oral contraceptive use and breast cancer has led to intensive research, but studies have provided inconsistent results causing confusion among clinicians. It was noticed that the risk of breast cancer was slightly elevated in current and recent young oral contraceptives users. That finding could be influenced by a detection bias or could be due to the biologic effect of the pills. The absolute number of additional breast cancer cases will be very small because of low baseline incidence of the disease in young women. Oral contraceptives probably promote growth of the already existing cancer, they are probably promoters not initiators of breast cancer. The available data do not provide a conclusive answer that is need. Cervical cancer. Numerous factors may influence the development of cervical cancer. The evidence suggests that current and recent oral contraceptive users have an increased risk of cervical cancer which decline after discontinuation of the application of medication. Oral contraceptives might increase the biological vulnerability of the cervix. Cervical cancer develops slowly over a long time period and can be effectively prevented by periodic cervical screening. Fortunately, oral contraceptives do not mask abnormal cervical citology. Conclusions regarding invasive cervical cancer and oral contraceptive use are not definitive but if there is any increased risk, it is low. Endometrial cancer. In oral contraceptive users the endometrium is almost under the influence of progestin component which suppresses endometrial mitotic activity and its proliferation. Most epidemiologic studies show that oral contraceptives reduce the risk of endometrial cancer and that this protective effect exists many years after the discontinuation of medication. Ovarian cancer. It has been long known that the oral contraceptive use causes protective an ovulation and reduces the risk of ovarian cancer. This powerful reduction is the best demonstrated major benefit of oral contraception. This protection is especially observed in nulliparous and seems to persist for many years after the discontinuation of medication.


2020 ◽  
pp. 1-8
Author(s):  
Alexis C. Edwards ◽  
Sara Larsson Lönn ◽  
Casey Crump ◽  
Eve K. Mościcki ◽  
Jan Sundquist ◽  
...  

Abstract Background Oral contraceptive use has been previously associated with an increased risk of suicidal behavior in some, but not all, samples. The use of large, representative, longitudinally-assessed samples may clarify the nature of this potential association. Methods We used Swedish national registries to identify women born between 1991 and 1995 (N = 216 702) and determine whether they retrieved prescriptions for oral contraceptives. We used Cox proportional hazards models to test the association between contraceptive use and first observed suicidal event (suicide attempt or death) from age 15 until the end of follow-up in 2014 (maximum age 22.4). We adjusted for covariates, including mental illness and parental history of suicide. Results In a crude model, use of combination or progestin-only oral contraceptives was positively associated with suicidal behavior, with hazard ratios (HRs) of 1.73–2.78 after 1 month of use, and 1.25–1.82 after 1 year of use. Accounting for sociodemographic, parental, and psychiatric variables attenuated these associations, and risks declined with increasing duration of use: adjusted HRs ranged from 1.56 to 2.13 1 month beyond the initiation of use, and from 1.19 to 1.48 1 year after initiation of use. HRs were higher among women who ceased use during the observation period. Conclusions Young women using oral contraceptives may be at increased risk of suicidal behavior, but risk declines with increased duration of use. Analysis of former users suggests that women susceptible to depression/anxiety are more likely to cease hormonal contraceptive use. Additional studies are necessary to determine whether the observed association is attributable to a causal mechanism.


2018 ◽  
Vol 17 (1) ◽  
pp. 1-8
Author(s):  
Niki Ververidou ◽  
Nafsika-Georgia Servitzoglou ◽  
Anastasios Siountas ◽  
Dimitrios Vavilis ◽  
David Rousso ◽  
...  

The influence of consumption of contraceptives to female body’s hormones could affect bone formation. The purpose of this study was to assess any possible change in bone density of young women who were taking oral contraceptives, compared with those who were not. Women who participated in this study were 18-25 years old and were divided into two groups, experimental and control. Contraceptive tablets containing 20 μgrs ethinyl estradiol and 3 mgr drosperinonis were given to women of the experimental group for 21 days. Data necessary for every woman was recorded (weight, height, gynecological age, chronological age). Bone density was measured at the lumbar spine [O2-O4] and femoral neck with the DEXA method [DMS Challenger]. Measurements were taken at the beginning of the study and after the period of 12 and 24 months. Our study concluded that oral contraceptive use did not cause any significant change to bone density group of young women.


Author(s):  
Theresa Nacey

Purpose: To explore the relationship between migraine and incidence of stroke in young women by analyzing variables of oral contraceptive use, hypercoagulability, cardiac abnormalities, and silent brain infarcts. Method:Variables were reviewed through computerized databases and current literature examining evidence-based medicine studies specific to analyzing the incidence of strokes in women with migraines. Results: Six recent studies, four case control and two cohort studies, were identified. Research outcomes indicate that the risk of stroke is greater in women less than 35 years of age who had migraine with aura and who used oral contraceptives. Other pathophysiologic variables, which may link migraine to stroke, include hypercoagulability, cardiac abnormalities, and silent brain infarcts. Conclusion: Young women with migraine appear to be at higher risk of ischemic stroke than women without migraine. This risk is further increased by the co-existence of other established risks including hypertension, smoking, and oral contraceptives. Patent foramen ovale, silent brain infarcts, and hypercoagulability are underlying mechanisms that appear to link migraine to stroke. Clinical studies and research into the pathophysiology of migraine is essential to explain why migraine patients are at higher risk of ischemic stroke.


2003 ◽  
Vol 14 (1) ◽  
pp. 57-60 ◽  
Author(s):  
Szilvia Vad ◽  
Gabriella Lakos ◽  
Emese Kiss ◽  
Sàndor Sipka ◽  
Roland Csorba ◽  
...  

2020 ◽  
Vol 6 (1) ◽  
Author(s):  
Takuji Ota ◽  
Toshiya Kamiyama ◽  
Takuya Kato ◽  
Takayuki Hanamoto ◽  
Kunihiro Hirose ◽  
...  

Abstract Background Hepatic cavernous hemangioma (CH) is the most common hepatic benign tumor. Most cases are solitary, asymptomatic, and found incidentally. In symptomatic cases with rapidly growing tumors and coagulopathy, surgical treatment is considered. In rare cases, diffuse hepatic hemangiomatosis (DHH) is reported as a comorbidity. The etiology of DHH is unknown. Case presentation A 29-year-old female patient had a history of endometriosis treated with oral contraceptives. Hepatic CH was incidentally detected in the segment IVa of the liver according to the Couinaud classification. Follow-up computed tomography (CT) and ultrasound sonography showed the growth of the lesion and formation of multiple new lesions near the first. Enhanced CT and magnetic resonance imaging (MRI) revealed that the new lesions were different from CH. Although oral contraceptives were stopped, all lesions grew in size. Malignancy and possibility of rupture of these tumors were considered due to the clinical course, and we opted for surgical removal of the tumors. Left liver lobectomy and cholecystectomy were performed. Surgical findings were small red spot spreading and a mass in segment IV of the liver. Pathological examination revealed a circumscribed sponge-like tumor with diffuse irregular extension to the adjacent area. Both of the lesions consisted of blood-filled dilated vascular spaces lined by flat endothelium without atypia. The diagnosis was hepatic CH with DHH. The patient was discharged on postoperative day 12 uneventfully. Conclusion We report the successful resection of CH with DHH. The case findings suggest a relationship between oral contraceptive use and enlargement of CH and DHH. Although DHH has been poorly understood, a few previously published cases reported DHH occurrence in patients using oral contraceptives. In such cases, the decision to perform surgical resection should be made after careful examination.


1995 ◽  
Vol 4 (2) ◽  
pp. 115-120
Author(s):  
Robert F Casper ◽  
Selim Senoz ◽  
Avraham Ben-Chetrit

Oral contraceptives remain the most widely used form of contraception in North America and Europe today. In spite of the concerns of many women relating to the potential risks of these preparations, recent data have demonstrated that currently available oral contraceptives are safe, with no increased risk of cardiovascular disease or cancer in nonsmoking women. The present review will focus on the impact of oral contraceptive use in the older woman, including a discussion of the noncontraceptive health benefits of oral contraceptives.


1992 ◽  
Vol 30 (14) ◽  
pp. 56.1-56

In our article on oral contraceptives (OCs) we state that ‘oral contraceptives increase the risk of breast cancer with long-term use but reduce the risk of endometrial and ovarian cancer’. Some commentators have questioned the breast cancer risk. The UK National Case-Control (UKNCC) study, which looked at oral contraceptive use in women with breast cancer diagnosed before age 36, found a trend for increased risk associated with duration of use.1 ‘The simplest and most plausible explanation’, say the authors of the study, ‘must be that there is a substantial causal relation between prolonged use and breast cancer in young women.’ The increased risk seems to be associated particularly with OC use before the first full-term pregnancy.2 Several studies found no excess risk in OC users aged 45 or over, few of whom had taken the pill before their first pregnancy.3–5 In the UKNCC study the relative risk of breast cancer was 1.43 after 4–8 years’ use and 1.74 after more than 8 years’ use. In broad terms this means that three women in 1000 who use oral contraceptives for 4 or more years might be expected to be under treatment for breast cancer by age 36, compared with two per 1000 non-users.


Sign in / Sign up

Export Citation Format

Share Document